HCM
HUTCHMED
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$14.18
+0.93%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$14.11
From 52W high−11.65%
Volume28369.00
Market cap$2.47B
P/E (TTM)144.7x
P/S (TTM)4.5x
Div yield—
Key dataOct 19, 2026
Open
$14.11
From 52W high
−11.65%
Volume
28369.00
Market cap
$2.47B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−58.8x
P/E (TTM)
144.7x
RSI (14)
55.1
MomentumView details →
1D Return
+0.93%
YTD Return
+6.38%
SummaryUpdated Jun 1, 2026
HUTCHMED (China) Limited (NASDAQ:HCM) is a Hong Kong-based biopharmaceutical company that was founded in 2000 and went public in 2016. Originally known as Hutchison China MediTech Limited, the company rebranded to HUTCHMED in May 2021. The company specializes in discovering, developing, and commercializing targeted cancer therapies and immunological treatments, with operations spanning Hong Kong and international markets. HUTCHMED has evolved from a research-focused organization into a commercial-stage company with multiple approved drugs and a robust pipeline of investigational treatments.
Similar companies
Latest newsMore news →
AstraZeneca filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer, as disclosed by HUTCHMED.21d agoHUTCHMED submitted a US New Drug Application for ORPATHYS plus TAGRISSO for MET-driven EGFR-mutated lung cancer after progression on EGFR-TKI therapy.21d agoChinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.29d ago